HLTH RSI Chart
Last 7 days
-15.4%
Last 30 days
-26.7%
Last 90 days
-56.0%
Trailing 12 Months
-83%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 328.8M | 251.0M | 198.9M | 70.9M |
2022 | 733.0M | 683.3M | 529.2M | 483.5M |
2021 | 171.7M | 320.5M | 469.3M | 618.1M |
2020 | 0 | 0 | 14.8M | 23.0M |
2019 | 0 | 0 | 0 | 6.6M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 25, 2024 | sever clint | sold (taxes) | -3,886 | 0.19 | -20,456 | chief executive officer |
Mar 05, 2024 | sever clint | sold (taxes) | -3,151 | 0.25 | -12,604 | chief product officer |
Mar 05, 2024 | javed aasim | sold (taxes) | -3,331 | 0.25 | -13,327 | chief financial officer |
Mar 05, 2024 | achar christopher k | sold (taxes) | -2,120 | 0.25 | -8,482 | - |
Mar 05, 2024 | pollard randall e. | sold (taxes) | -1,826 | 0.25 | -7,304 | chief accounting officer |
Mar 05, 2024 | khattak ayub k | sold (taxes) | -2,685 | 0.25 | -10,742 | president and ceo |
Feb 16, 2024 | reddy rishi | acquired | - | - | 63,300 | - |
Feb 08, 2024 | khattak ayub k | acquired | - | - | 700,000 | president and ceo |
Feb 08, 2024 | javed aasim | acquired | - | - | 500,000 | chief financial officer |
Feb 08, 2024 | achar christopher k | acquired | - | - | 300,000 | - |
Which funds bought or sold HLTH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Cubist Systematic Strategies, LLC | new | - | 6,295 | 6,295 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -22.45 | - | - | -% |
May 15, 2024 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | sold off | -100 | -1,024 | - | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | sold off | -100 | -3,374 | - | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -29.71 | -7,498 | 33,204 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 13,300 | 13,300 | -% |
May 15, 2024 | TWO SIGMA ADVISERS, LP | reduced | -16.48 | -704 | 22,274 | -% |
May 15, 2024 | MSD Partners, L.P. | unchanged | - | 10,316 | 74,544 | 0.01% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -60.57 | -4,475 | 3,768 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | reduced | -27.41 | -100,506 | 537,614 | -% |
Unveiling Nobilis Health Corp's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Nobilis Health Corp)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 476.5B | 379.5B | 31.02 | 1.26 | ||||
CI | 97.6B | 206.0B | 25.32 | 0.47 | ||||
HCA | 85.6B | 66.7B | 15.65 | 1.28 | ||||
CVS | 70.6B | 360.9B | 9.64 | 0.2 | ||||
CNC | 41.7B | 155.5B | 15.24 | 0.27 | ||||
UHS | 12.3B | 14.7B | 15 | 0.84 | ||||
DVA | 12.1B | 12.3B | 14.83 | 0.98 | ||||
MID-CAP | ||||||||
CHE | 8.6B | 2.3B | 30.3 | 3.74 | ||||
ACHC | 6.4B | 3.0B | -564.83 | 2.13 | ||||
AMEH | 2.3B | 1.5B | 36.92 | 1.59 | ||||
AMN | 2.3B | 3.5B | 15.9 | 0.66 | ||||
SMALL-CAP | ||||||||
ADUS | 1.8B | 1.1B | 27.64 | 1.67 | ||||
BKD | 1.4B | 3.0B | -7.9 | 0.45 | ||||
BEAT | 56.6M | - | -3.75 | - | ||||
AMS | 21.7M | 21.6M | 39.33 | 1 |
Nobilis Health Corp News
Income Statement (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Revenue | 7.6% | 18,798,000 | 17,477,000 | 9,896,000 | 24,765,000 | 146,777,000 | 69,589,000 | 87,700,000 | 179,410,000 | 192,506,000 | 223,679,000 | 137,423,000 | 64,499,000 | 34,614,500 | 4,730,000 | - |
Operating Expenses | 104.1% | 167,703,000 | 82,182,000 | 95,289,000 | 120,615,000 | 185,401,000 | 137,002,000 | 190,163,000 | 176,562,000 | 169,125,000 | 136,304,000 | 72,715,000 | 49,744,000 | - | 13,232,000 | - |
S&GA Expenses | -11.7% | 6,226,000 | 7,051,000 | 8,059,000 | 11,248,000 | 19,312,000 | 18,129,000 | 16,971,000 | 34,168,000 | 21,198,000 | 5,572,000 | 1,529,000 | 430,000 | - | 19,000 | - |
R&D Expenses | -13.1% | 32,248,000 | 37,103,000 | 36,536,000 | 44,733,000 | 56,149,000 | 42,516,000 | 44,000,000 | 28,787,000 | 21,679,000 | 9,079,000 | 4,662,000 | 7,409,000 | - | 6,878,000 | - |
EBITDA Margin | -321.3% | -4.39 | -1.04 | -0.93 | -0.77 | -0.33 | -0.20 | 0.02 | 0.20 | 0.25 | -0.09 | -0.13 | -0.24 | -1.77 | -1.14 | - |
Interest Expenses | - | - | - | - | - | 645,000 | - | - | - | 9,049,000 | - | 493,000 | 267,000 | - | - | - |
Income Taxes | -98.7% | 60,000 | 4,733,000 | - | - | -5,315,000 | -1,047,000 | -3,386,000 | - | -10,615,000 | 30,098,000 | 12,050,000 | 1,226,000 | - | - | - |
Earnings Before Taxes | -251.3% | -148,372,000 | -42,237,000 | -83,864,000 | -94,198,000 | -36,821,000 | -67,350,000 | -102,436,000 | 2,803,000 | 23,615,000 | 49,446,000 | 31,859,000 | 14,257,000 | - | -8,538,000 | - |
EBT Margin | -302.1% | -5.20 | -1.29 | -1.12 | -0.91 | -0.42 | -0.27 | -0.04 | 0.15 | 0.19 | -0.10 | -0.15 | -0.28 | -2.06 | -1.39 | - |
Net Income | -216.0% | -148,432,000 | -46,970,000 | -83,864,000 | -94,198,000 | -31,506,000 | -66,303,000 | -99,050,000 | 2,803,000 | 34,230,000 | 19,348,000 | 19,809,000 | 13,031,000 | - | -8,538,000 | - |
Net Income Margin | -308.2% | -5.26 | -1.29 | -1.10 | -0.89 | -0.40 | -0.24 | -0.06 | 0.10 | 0.14 | -0.10 | -0.15 | -0.28 | -2.06 | -1.39 | - |
Free Cashflow | -112.0% | -30,090,000 | -14,196,000 | -44,905,000 | -57,789,000 | -58,702,000 | -52,306,000 | -69,831,000 | 18,739,000 | -25,362,000 | 1,422,000 | -28,753,000 | -65,604,000 | - | - | - |
Balance Sheet | ||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2020Q4 |
Assets | -31.0% | 340 | 492 | 524 | 609 | 695 | 825 | 914 | 984 | 940 | 922 | 316 |
Current Assets | -42.6% | 110 | 192 | 212 | 287 | 371 | 522 | 620 | 701 | 670 | 670 | 184 |
Cash Equivalents | -27.4% | 81.00 | 111 | 129 | 178 | 242 | 305 | 363 | 426 | 410 | 447 | 129 |
Inventory | -77.9% | 14.00 | 64.00 | 68.00 | 82.00 | 82.00 | 133 | 139 | 133 | 88.00 | 71.00 | 37.00 |
Liabilities | -13.5% | 90.00 | 103 | 101 | 113 | 118 | 235 | 274 | 259 | 233 | 268 | 241 |
Current Liabilities | -25.6% | 43.00 | 58.00 | 57.00 | 67.00 | 71.00 | 175 | 210 | 192 | 167 | 182 | 156 |
Shareholder's Equity | -35.6% | 250 | 389 | 423 | 496 | 576 | 590 | 640 | 725 | 707 | 654 | -101 |
Retained Earnings | -33.5% | -591 | -443 | -396 | -312 | -218 | -186 | -120 | -21.21 | -24.02 | -58.25 | -110 |
Additional Paid-In Capital | 1.2% | 842 | 832 | 819 | 808 | 795 | 777 | 761 | 746 | 731 | 713 | 9.00 |
Shares Outstanding | 0.5% | 155 | 155 | 153 | 152 | 150 | 147 | 147 | 147 | 53.00 | 32.00 | 16.00 |
Float | - | - | - | 50.00 | - | - | - | 334 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Cashflow From Operations | -129.0% | -28.72 | -12.54 | -42.66 | -53.88 | -51.70 | -39.91 | -51.83 | 32.00 | 9.00 | 20.00 | -2.70 | -35.11 | - | - | - |
Share Based Compensation | -20.1% | 10.00 | 13.00 | 12.00 | 14.00 | 16.00 | 16.00 | 17.00 | 16.00 | 17.00 | 19.00 | 4.00 | 3.00 | - | - | - |
Cashflow From Investing | 49.8% | -1.83 | -3.66 | -5.99 | -8.32 | -10.09 | -18.27 | -20.62 | -14.05 | -37.56 | -19.26 | -27.05 | -31.84 | - | - | - |
Cashflow From Financing | 98.9% | -0.01 | -0.90 | -1.00 | -1.13 | -1.87 | -0.30 | -3.39 | -0.87 | -6.17 | 206 | 163 | 57.00 | - | - | - |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue | |||
Revenue | $ 70,936,000 | $ 483,476,000 | $ 618,107,000 |
Operating costs and expenses: | |||
Sales and marketing | 32,584,000 | 88,580,000 | 28,729,000 |
Research and development | 150,620,000 | 171,452,000 | 42,829,000 |
General and administrative | 57,355,000 | 97,103,000 | 79,788,000 |
Impairment of long-lived assets | 83,639,000 | 0 | 0 |
Restructuring expense | 14,500,000 | 2,020,000 | 0 |
Total operating costs and expenses | 465,789,000 | 689,128,000 | 427,888,000 |
(Loss) income from operations | (394,853,000) | (205,652,000) | 190,219,000 |
Interest income | 6,240,000 | 3,328,000 | 108,000 |
Interest expense | (1,159,000) | (645,000) | (9,809,000) |
Change in fair value of redeemable convertible preferred stock warrants | 0 | 0 | 53,000 |
Change in fair value of convertible notes | 0 | 0 | (59,560,000) |
Loss on extinguishment of debt | 0 | 0 | (1,998,000) |
Tax credits | 20,939,000 | 0 | 0 |
Other income (expense), net | 162,000 | (835,000) | 164,000 |
Net (loss) income before income taxes | (368,671,000) | (203,804,000) | 119,177,000 |
Income tax expense (benefit) | 4,793,000 | (9,748,000) | 32,759,000 |
Net (loss) income | $ (373,464,000) | $ (194,056,000) | $ 86,418,000 |
Net (loss) income per share attributable to common stockholders – basic (in dollars per share) | $ (2.44) | $ (1.31) | $ 0.63 |
Weighted-average number of shares used in computation of net (loss) income per share attributable to common stockholders – basic (in shares) | 152,877,306 | 148,024,749 | 52,815,449 |
Net (loss) income per share attributable to common stockholders – diluted (in dollars per share) | $ (2.44) | $ (1.31) | $ 0.59 |
Weighted-average number of shares used in computation of net (loss) income per share attributable to common stockholders – diluted (in shares) | 152,877,306 | 148,024,749 | 59,635,384 |
Product revenue | |||
Revenue | |||
Revenue | $ 64,223,000 | $ 474,166,000 | $ 615,796,000 |
Operating costs and expenses: | |||
Cost of product revenue | 127,091,000 | 329,973,000 | 276,542,000 |
Grant and other revenue | |||
Revenue | |||
Revenue | $ 6,713,000 | $ 9,310,000 | $ 2,311,000 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 80,889 | $ 241,530 |
Restricted cash | 800 | 800 |
Accounts receivable, net of allowance for credit losses ($22 and $2,311, respectively) | 1,352 | 18,751 |
Inventories, net - current | 14,039 | 82,210 |
Prepaid expenses | 8,479 | 15,728 |
Other current assets | 4,803 | 12,134 |
Total current assets | 110,362 | 371,153 |
Non-current inventories | 56,273 | 25,436 |
Property and equipment, net | 72,096 | 189,275 |
Right-of-use assets operating leases | 78,519 | 85,321 |
Intangible assets, net | 19,644 | 16,867 |
Other non-current assets | 2,893 | 6,528 |
Total assets | 339,787 | 694,580 |
Current liabilities: | ||
Accounts payable | 7,705 | 7,150 |
Accrued liabilities and other current liabilities | 29,300 | 52,378 |
Deferred revenue, current | 162 | 1,566 |
Operating lease liabilities, current | 5,142 | 7,739 |
Finance lease liabilities, current | 1,157 | 2,362 |
Total current liabilities | 43,466 | 71,195 |
Operating leases liabilities, net of current portion | 41,640 | 44,045 |
Finance lease liabilities, net of current portion | 0 | 849 |
Other non-current liabilities | 4,429 | 1,997 |
Total liabilities | 89,535 | 118,086 |
Commitments and contingencies | ||
Stockholders’ Equity | ||
Common stock, $0.00001 par value; 500,000,000 and 500,000,000 shares authorized, 155,304,764 and 150,406,014 issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 2 | 1 |
Additional paid-in-capital | 841,788 | 794,567 |
Accumulated deficit | (591,538) | (218,074) |
Total stockholders’ equity | 250,252 | 576,494 |
Total liabilities and stockholders’ equity | $ 339,787 | $ 694,580 |
 | Mr. Ayub K. Khattak |
---|---|
 | cuehealth.com |
 | Healthcare Plans |
 | 1515 |